Elizabeth Rozek
Known title: General Counsel and CCOCIK: 0001975022
Associated companies
Transaction History
| SGMT | ▼ Sell | Open Market | 10,545 | $82K | 7/20/2026 | View on chart |
| SGMT | ▲ Buy | Grant | 44,000 | $0 | 2/19/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 2,622 | $14K | 2/10/2026 | View on chart |
| SGMT | ▲ Buy | Grant | 9,855 | $0 | 11/4/2025 | View on chart |
| SGMT | ▼ Sell | Open Market | 10,780 | $98K | 7/21/2025 | View on chart |
| SGMT | ▲ Buy | Grant | 34,000 | $0 | 2/6/2025 | View on chart |
| SGMT | ▼ Sell | Open Market | 10,914 | $34K | 7/19/2024 | View on chart |
| SGMT | ▲ Buy | Grant | 171,420 | $0 | 11/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target
Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.